Immatics (IMTX) Net Equity Issued and Repurchased (2020 - 2025)
Immatics (IMTX) reported Net Equity Issued and Repurchased of $124.9 million for Q4 2025, down 30.62% on a YoY basis from $180.0 million in Q4 2024, and up 2670825.82% sequentially from $4676.2 in Q3 2025.
Immatics (IMTX) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Immatics (IMTX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $124.9 million in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased fell 30.62% year-over-year to $124.9 million; the trailing twelve-month figure through Dec 2025 stood at $305.0 million (down 17.51% YoY), and the FY2025 full-year result was $121.2 million, down 67.34% from the prior year.
- Net Equity Issued and Repurchased improved to $124.9 million in Q4 2025, from $4676.2 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $201.7 million in Q1 2024 to a low of -$97.2 million in Q4 2023.
- A 5-year average of $52.1 million and a median of $3.9 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
- Across the five-year window, Net Equity Issued and Repurchased soared 532544.04% in 2022 and tumbled 183.93% in 2023, its largest moves.
- Tracing IMTX's Net Equity Issued and Repurchased over 5 years: stood at $21735.4 in 2021, then soared by 532544.04% to $115.8 million in 2022, then plunged by 183.93% to -$97.2 million in 2023, then surged by 285.25% to $180.0 million in 2024, then plunged by 30.62% to $124.9 million in 2025.
- Business Quant data shows IMTX's Net Equity Issued and Repurchased at $124.9 million in Q4 2025, $4676.2 in Q3 2025, and $180.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Immatics | 1.14 Bn | 1.14 Bn | - | 124.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 124.90 Mn |
| Dec 31, 2025 | 124.90 Mn |
| Sep 30, 2025 | 4,676.22 |
| Sep 30, 2025 | 4,676.22 |
| Dec 31, 2024 | 180.01 Mn |
| Dec 31, 2024 | 180.01 Mn |
| Sep 30, 2024 | 85,661.12 |
| Sep 30, 2024 | 85,661.12 |
| Jun 30, 2024 | -12.05 Mn |
| Jun 30, 2024 | -12.05 Mn |
| Mar 31, 2024 | 201.70 Mn |
| Mar 31, 2024 | 201.70 Mn |
| Dec 31, 2023 | -97.17 Mn |
| Dec 31, 2023 | -97.17 Mn |
| Sep 30, 2023 | 56.38 Mn |
| Sep 30, 2023 | 56.38 Mn |
| Dec 31, 2022 | 115.77 Mn |
| Dec 31, 2022 | 115.77 Mn |
| Sep 30, 2022 | 3.93 Mn |
| Sep 30, 2022 | 3.93 Mn |